emjreviews.com
Cure8 news brief
New Model Predicts Crohn’s Disease Risk in Relatives
Research and clinical trials
Biomarkers
Microbiome
Fecal calprotectin
Biomarker
Clinical study
Adult patients
Parents Caregivers
Why This Matters
This model aims to identify healthy first‑degree relatives at higher risk of developing Crohn’s disease before symptoms start, which could enable earlier monitoring or preventive strategies. The score uses simple biomarkers (like faecal calprotectin) plus microbiome data rather than just genetics alone.
Who Should Pay Attention
First‑degree relatives of people with Crohn’s disease, clinicians who manage IBD or family screening, and researchers studying biomarkers and the microbiome in disease prediction.
Study Snapshot
Story typeResearch news
Evidence typeClinical study
Source depthFull source text
What To Know
New research developed the GEM-IRS, an integrative risk score that combines demographics, physiologic biomarkers (including faecal calprotectin and lactulose–mannitol ratio), and faecal microbiome data to predict future Crohn’s disease in healthy first‑degree relatives.
The model was trained and validated using cohorts from the GEM study (North America and Israel) and showed strong discrimination in the training set and moderate-to-strong performance in testing cohorts.
Fecal calprotectin and the lactulose–mannitol ratio were among the top contributors, along with specific gut microbes (for example, Holdemania, Gemella, and Ruminococcus torques). The study reports that individuals in the highest GEM-IRS quartile had a substantially higher cumulative incidence of Crohn’s disease than those in lower quartiles.
The article notes the need for further validation before clinical use and suggests the score might help identify asymptomatic high‑risk relatives for early monitoring or preventive interventions.
If you are a relative of someone with Crohn’s disease and are curious about personal risk, this research describes a new multi-component tool that could eventually be used in clinical risk assessment, but it is not yet a routine clinical test.
Keep In Mind
The GEM‑IRS is from a multicenter prospective cohort and performed well in the reported datasets, but the article and cited study emphasize further external validation is needed. This is prediction research, not a proven preventive intervention; results should be interpreted cautiously and discussed with clinicians.
Source Details
Review the original publication for the complete reporting, methods, and context.
Clinical study
Article type assigned from Cure8 classification; confirm details in the original source.
Publicationemjreviews.com
Indexed viaBing News
Source typeResearch news
PublishedJan 11, 2025, 2:00 AM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Understanding role of microbiota in Crohn's disease, ulcerative colitis
The article explains how gut bacteria may contribute to IBD and summarizes common tests and treatments people are likely to encounter. It highlights emerging microbial therapies (probiotics and FMT) that some patients...
A very common vitamin has surprised scientists and is forcing them to rethink how to manage inflammation in Crohn’s disease and colitis
The study suggests vitamin D might help the immune system tolerate gut bacteria better and lower intestinal inflammation, which could mean fewer symptoms or flares for people with Crohn’s disease or ulcerative colitis.
Wolfe Highlights Differentiation Potential in Palisade Bio, Inc. (PALI) Clinical Profile
Early clinical data suggest PALI-2108 may affect both inflammation and fibrosis in Crohn’s disease and shows biomarker changes (like fecal calprotectin) that could matter to people monitoring disease activity.